In a groundbreaking move for the treatment of hypercholesterolemia, Merck has secured FDA approval for Lipfendra, its innovative oral medication that serves as the first in its class of PCSK9 inhibitors aimed at managing cholesterol levels through a daily tablet.
INDIANAPOLIS — Thursday marked a milestone as the FDA greenlit an unprecedented cholesterol-lowering medication, designed specifically to combat hypercholesterolemia.
In its announcement, Merck proudly introduced Lipfendra, also known scientifically as enlicitide, highlighting its position as the inaugural oral PCSK9 inhibitor.
Hypercholesterolemia is characterized by excessively high levels of low-density lipoprotein (LDL) cholesterol, often dubbed as the “bad” cholesterol, which can accumulate plaque within arterial walls. Reports from the Cleveland Clinic indicate that this condition affects approximately 5% of the population. The disorder can stem from genetic factors or lifestyle choices, such as diets rich in saturated and trans fats, and other health considerations.
“This represents a significant advancement in providing adults with elevated LDL-C levels the first FDA-approved oral PCSK9 inhibitor, offering them a vital new treatment alternative,” expressed Dr. Dean Y. Li, who stands as the president of Merck Research Laboratories.
Lipfendra works by blocking the PCSK9 protein, which helps regulate cholesterol levels. Trials showed the once-daily pill significantly lowered LDL cholesterol in patients. While there are already PCSK9-inhibitor injectables, this is the first FDA-approved oral PCSK9 Inhibitor.
An ongoing clinical trial is studying the effect of Lipfendra on cardiovascular morbidity and mortality.